Immunologic Factor – Page 7

Incyte’s Zynyz Secures FDA Approval for Anal Cancer After Previous Rejection

2 months ago talkbio0Tagged Approved, Clinical Trials, Combination Drug Therapy, first-line therapy, Immunotherapy, Incyte, Inhibitor, Malignant neoplasm of anus, PDCD1 gene, POD1UM-303, Retifanlimab, United States Food and Drug Administration, Zynyz

Incyte; Zynyz; retifanlimab; FDA approval; anal cancer; PD-1 inhibitor; first-line therapy; immunotherapy; clinical trial; POD1UM-303; combination chemotherapy

AbbVie Advances Solid Tumor Program with FDA Approval of Emrelis for Lung Cancer

2 months ago talkbio0Tagged AbbVie, Accelerated, ADC, Approved, Emrelis, Malignant neoplasm of lung, MET protein, human, Non-Small Cell Lung Carcinoma, Protein Overexpression, Solid Neoplasm, Telisotuzumab, therapeutic autologous dendritic cells, United States Food and Drug Administration, vedotin-tllv

AbbVie; Emrelis; FDA Approval; ADC; solid tumor; lung cancer; non-small cell lung cancer; c-Met overexpression; telisotuzumab vedotin-tllv; accelerated approval

Merck’s Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights

2 months ago talkbio0Tagged AACR, Cancer of Neck, Clinical Trials, Event-Free Survival, Head, KEYNOTE-689 trial, Keytruda, locally advanced head, Merck, pembrolizumab, perioperative, recurrence prevention, Squamous cell carcinoma, United States Food and Drug Administration

Keytruda; Merck; AACR 2025; head and neck cancer; resectable locally advanced head and neck squamous cell carcinoma; event-free survival; KEYNOTE-689 trial; perioperative pembrolizumab; recurrence prevention; clinical trial; FDA

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

2 months ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

3 months ago talkbio0Tagged Biosciences, Biotech Layoffs, Collaboration termination, Facility (object), IgM antibodies, Immunoglobulin M, Immunology, Inflammation, Neoplasms, Reparative closure, sanofi

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology

AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients

3 months ago talkbio0Tagged Clinical Trials, expansion, high-risk, Imfinzi, Malignant neoplasm of urinary bladder

Imfinzi, Clinical Trials, high-risk, expansion, Malignant neoplasm of urinary bladder

Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit

3 months ago talkbio0Tagged cynicism, Immune response, mandates, Misinformation, Offit, Paul Offit, Urinary hesitation, Vaccines

Vaccines, Urinary hesitation, Offit, cynicism, Misinformation, Immune response, Paul Offit, mandates

Vinay Prasads FDA Appointment Anything but Status Quo

3 months ago talkbio0Tagged Anything, Appointments, Prasad, Prasad 's, Status Quo, United States Food and Drug Administration, Vaccines

United States Food and Drug Administration, Appointments, Vaccines, Prasad, Prasad ‘s, Anything, Status Quo

FDA Vaccine Advisory Committee to Determine 2025-2026 COVID-19 Vaccine Formulation

3 months ago talkbio0Tagged Advisory Committees, COVID19 (disease), Formula - diet, meeting, strain selection, United States Food and Drug Administration, Vaccines, VRBPAC

COVID-19 vaccines, FDA advisory committee, strain selection, 2025-2026 formula, vaccine updates, VRBPAC meeting

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

3 months ago3 months ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1